BUSINESS
Boehringer Speeding Up Growth of Jardiance on Organization, Alliance Rejig; 40 Billion Yen Japan Sales Likely in 2020
Nippon Boehringer Ingelheim is increasing its investment in Jardiance (empagliflozin), the top selling SGLT2 inhibitor, to further accelerate growth. The company positions the drug as the main driver of growth of its primary care business, with sales of the family…
To read the full story
BUSINESS
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





